TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.

Shukui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.